AI Consensus Investment Thesis
Teladoc Health (TDOC) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
BUY
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY$7.58
+20.2%5-Year
BUY$13
+102.5%Latest flagship insight
Virtual Care Pioneer Navigates Looming Convertible Debt Wall Amid Chronic Margin Inflection
Analyses reveal sharp divergence regarding normalized free cash flow durability, yet high consensus that core enterprise integrated care provides essential operational ballast. While direct-to-consumer therapy suffers ongoing attrition, substantial balance-sheet liquidity and expanding commercial payer reimbursements buffer upcoming convertible debt maturities against immediate insolvency risks.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
J.P. Morgan (Titan), Universal Investor (Polymath), Warren Buffett (Value Purist), Michael Burry (Vulture), Machiavelli (Insider), Ray Dalio (Strategist), Superintelligence (Anthropologist), Elon Musk (Visionary), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Teladoc Health at the forecast anchor (2026-09-18): $20,248 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 6.33 | +0.53% | +0.53% | Third-quarter results reflect persistent consumer therapy contraction and seasonal digital ad inflation. Year-end tax-loss selling and looming convertible debt maturities keep sentiment depressed, though positive underlying operating cash flow prevents further structural breakdown. |
| Q1 2027 | 6.66 | +5.12% | +5.67% | Full-year reporting and forward guidance clarify the commercial insurance transition at BetterHelp. Management outlines an executable framework utilizing liquid cash reserves to address upcoming convertible debt, initiating modest multiple stabilization from distressed levels. |
| Q2 2027 | 7.21 | +8.26% | +14.40% | The June convertible maturity dominates market dynamics. Cash settlement and modest replacement credit lines neutralize immediate solvency risk without common equity dilution, triggering sharp institutional short-covering despite temporary liquidity drawdowns. |
| Q3 2027 | 7.58 | +5.11% | +20.25% | Post-refinancing clarity establishes a renewed fundamental baseline. Higher interest expense on replacement debt tempers enthusiasm, but expanding chronic care enrollment and initial commercial insurance reimbursement gains support sequential operational stabilization. |
| Q4 2027 | 7.96 | +5.12% | +26.40% | Autumn employer health plan selling season confirms solid enterprise retention across Fortune 500 accounts. Narrowing net losses and reduced stock-based compensation demonstrate sustained overhead discipline, supporting gradual multiple recovery into year-end. |
| Q1 2028 | 8.37 | +5.05% | +32.79% | Full-year 2027 financials demonstrate adjusted EBITDA resilience and positive post-software free cash flow. As solvency fears recede permanently, fundamental value investors re-rate the business toward historical healthcare IT utility multiples. |
| Q2 2028 | 8.77 | +4.79% | +39.16% | BetterHelp commercial insurance sessions scale, partially offsetting legacy cash-pay attrition. Ambient clinical documentation tools lower provider administrative burdens, expanding gross margins toward seventy percent and confirming operational turnaround feasibility. |
| Q3 2028 | 8.92 | +1.78% | +41.64% | Mid-year consultation seasonality and competitive pricing pressure from captive payer telehealth networks moderate top-line momentum. Underlying cash generation remains steady, allowing the balance sheet to absorb modest working-capital fluctuations without strain. |
| Q4 2028 | 9.31 | +4.33% | +47.76% | Enterprise contract renewals show healthy uptake of bundled cardiometabolic and weight-management programs. Disciplined capital allocation and growing cash reserves support equity valuation, offsetting continued low-single-digit top-line drag in consumer mental health. |
| Q1 2029 | 9.69 | +4.05% | +53.74% | Full-year 2028 results mark an inflection toward GAAP operating breakeven as historical acquisition amortization drops off the income statement. Eliminating accounting deficits attracts quantitative institutional screens, driving steady equity accumulation. |
| Q2 2029 | 10.04 | +3.63% | +59.32% | Commercial insurance integration at BetterHelp matures, establishing predictable recurring session gross profits. Voluntary early term debt paydowns reduce annual interest burdens, directly lifting per-share cash generation and de-risking the capital structure. |
| Q3 2029 | 10.31 | +2.70% | +63.62% | Summer seasonal consultation lulls prompt minor consolidation. However, entrenched provider integration across regional health plans defends high-margin recurring access fees, insulating the equity from broader macroeconomic and healthcare tech volatility. |
| Q4 2029 | 10.67 | +3.47% | +69.30% | Favorable open-enrollment additions across self-insured corporate accounts deliver strong top-line visibility for the upcoming fiscal year. Expanding adjusted EBITDA margins reflect cumulative administrative efficiencies, underpinning consistent quarterly share appreciation. |
| Q1 2030 | 11.00 | +3.12% | +74.58% | Full-year 2029 disclosures confirm sustained positive GAAP net income and robust free cash flow. Management evaluates shareholder-friendly capital return strategies, cementing market recognition of the company as an essential digital healthcare utility. |
| Q2 2030 | 11.20 | +1.85% | +77.80% | Automated clinical triage and AI-assisted provider workflows further compress delivery overhead per consultation. Operating leverage strengthens across Integrated Care, cushioning the platform against ongoing visit-based pricing concessions demanded by national payers. |
| Q3 2030 | 11.45 | +2.24% | +81.78% | Predictable operational execution across enterprise and behavioral segments maintains steady quarterly cash conversion. The equity trades in an orderly valuation channel, supported by mid-single-digit free cash flow compounding and pristine liquidity. |
| Q4 2030 | 11.85 | +3.51% | +88.16% | Year-end balance-sheet deleveraging leaves net cash in a robust surplus position. Stable chronic care subscriber retention balances mature direct-to-consumer therapy dynamics, providing dependable price support during annual portfolio rebalancing cycles. |
| Q1 2031 | 12.19 | +2.84% | +93.50% | Full-year 2030 earnings highlight clean operational profitability and negligible credit risk. Sell-side analysts upgrade coverage models to reflect a durable cash cow rather than a distressed speculative turnaround, sustaining upward momentum. |
| Q2 2031 | 12.47 | +2.34% | +98.02% | Mature-phase execution delivers predictable clinical encounter volumes across commercial and Medicare Advantage accounts. Modest payer pricing scrutiny is fully offset by overhead discipline, maintaining stable operating margins and consistent cash flow. |
| Q3 2031 | 12.76 | +2.25% | +102.48% | The five-year transformation concludes with the business valued as an indispensable, cash-generative healthcare software utility. Re-rated valuation multiples and accumulated balance-sheet cash deliver substantial cumulative recovery from trough entry levels. |
The investment thesis centers on an acute mispricing between perceived insolvency and durable enterprise cash generation. While direct-to-consumer therapy revenue contracts under marketing cost inflation, the B2B Integrated Care segment delivers an entrenched, high-margin subscription annuity across one hundred million covered lives. Forensic accounting reveals that headline free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry is flattered by software capitalization; normalized cash generation is approximately $120 million to $140 million rather than the headline $225 million. Nevertheless, existing liquidity and positive operational cash flow fully cover the June 2027 convertible maturity without requiring dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry recapitalization. Valuation sensitivity remains tied to refinancing costsrefinancing costsIncreased interest expenses incurred when rolling over existing debt at higher market rates.View full glossary entry and consumer stabilization.
Key insights
- Capitalized software accounts for over ninety percent of capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry, requiring investors to evaluate normalized cash conversion rather than flattering headline yields.
- Transitioning consumer therapy toward contracted commercial insurance expands patient addressability but introduces clinician credentialing bottlenecks and bureaucratic payer revenue collection delays.
- Resolving the convertible maturity removes binary distress discounts, yet higher replacement borrowing coupons permanently reduce net margins and per-share compounding velocity.
The company is undergoing a major transition from a troubled consumer app into a reliable digital healthcare utility. While its retail therapy brand is shrinking, its enterprise business quietly provides steady profits from millions of corporate employees. The business generates real cash and holds enough money to pay off its upcoming debt, meaning bankruptcy fears are heavily exaggerated. The stock should recover as these financial anxieties fade.
Key insights
- Steady corporate healthcare contracts generate reliable cash flow that helps cushion falling direct-to-consumer therapy sales.
- Ample balance-sheet cash ensures upcoming bond debts can be retired without diluting existing shareholder equity.
- Moving therapy services into insurance networks stabilizes membership but brings slower payment collections from insurers.
Deep Dive
Market consensus has dismissed the enterprise as an irrecoverable pandemic relic, anchored to historical goodwill write-downs and relentless revenue decay in consumer mental health. Investors widely assume that high customer acquisition costscustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry are fatal, treating the 2027 convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry wall as an existential solvency threat. Consequently, prevailing sentiment prices the equity at a distressed multipledistressed multipleA low valuation multiple assigned when investors price in elevated credit, earnings, or liquidity risk.View full glossary entry, convinced that dilutive recapitalization or operational insolvency is inevitable.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Market consensus has dismissed the enterprise as an irrecoverable pandemic relic, anchored to historical goodwill write-downs and relentless revenue decay in consumer mental health. Investors widely assume that high customer acquisition costscustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry are fatal, treating the 2027 convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry wall as an existential solvency threat. Consequently, prevailing sentiment prices the equity at a distressed multipledistressed multipleA low valuation multiple assigned when investors price in elevated credit, earnings, or liquidity risk.View full glossary entry, convinced that dilutive recapitalization or operational insolvency is inevitable.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates value due to an analytical blind spot that conflates consumer therapy headwinds with enterprise insolvency. The market overlooks that Integrated Care delivers resilient adjusted EBITDAadjusted ebitdaEBITDA modified to exclude selected items that management considers non-recurring or not representative of ongoing operations.View full glossary entry margins above sixteen percent across an entrenched B2B base, while $774 million in cash and positive operational cash flow provide sufficient liquidity to retire maturing convertible notes without dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry issuance. However, bulls who cite an unadjusted twenty percent free cash flow yieldfree cash flow yieldFree cash flow divided by market value, showing cash generation relative to the asset price.View full glossary entry ignore heavy software capitalization, meaning true intrinsic undervaluation is meaningful but moderate.
Repricing Catalyst
What could make the market recognize and close that gap? The decisive catalyst is the formal resolution of the $996.7 million convertible senior notes due June 1, 2027 through a combination of existing cash reserves and modest credit facilities. Retiring this liability without dilutive equitydilutive equityIssuance of new shares that reduces the ownership percentage and earnings per share for existing shareholders.View full glossary entry issuance dispels existential bankruptcy fears, compelling credit markets and institutional investors to re-evaluate the company on normalized cash earnings. The first observable confirmation will emerge via announced refinancing terms or cash tender repurchases during early 2027.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Extreme Fear
- Volatility
- High Erratic
- Cycle position
- Stabilization
Sentiment converges on severe pessimism regarding direct-to-consumer therapy churn, yet opinions diverge on cycle positioning between late capitulation and early stabilization. The decisive tension centers on whether debt maturity resolution triggers an immediate relief re-rating or a protracted multi-year grind.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of elevated central bank interest rates and restrictive credit conditions is a distinct headwind. High benchmark yields raise prospective borrowing costs when rolling over maturing debt and compress equity valuation multiples. However, corporate employer demand for cost-saving virtual healthcare benefits provides defensive operational insulation against broader macroeconomic deceleration.
Advisor Disagreement
What do our AI Advisors disagree about most? The most consequential analytical debate centers on true normalized cash generation and the ultimate fate of BetterHelp. One camp argues that reported trailing cash flow of $225 million reflects an unassailable twenty percent yield, paving the way for rapid balance-sheet de-leveraging. The opposing view demonstrates that deducting heavy capitalized software development cuts true cash flow near $130 million, while consumer churn will permanently depress top-line revenue. Reconciling this debate requires monitoring second-half 2026 cash conversion after capitalized software, alongside commercial insurance run-rates from the upcoming quarterly filings.
Base-Case Forces
Event Risk ScoreHigh69/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Enterprise Integrated Care contract stability | Competitive Positioning | +32% | +28% | Integrated Care serves over one hundred million members, delivering stable revenues and adjusted EBITDAadjusted ebitdaEBITDA modified to exclude selected items that management considers non-recurring or not representative of ongoing operations.View full glossary entry margins near 16.5%. Entrenched employer relationships and multi-condition cross-selling create substantial switching friction, defending core B2B cash flows against commoditizationcommoditizationThe process where services become indistinguishable, leading to price-based competition and severe margin erosion.View full glossary entry. This recurring enterprise earnings foundation insulates the business from retail therapy volatility and permanently finances ongoing digital health modernization. |
| Convertible note balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry derisking | Capital Allocation | +28% | +15% | Management possesses $774 million in cash alongside an undrawn revolving credit facility to address the $996.7 million convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry due June 2027. Retiring this liability through internal liquidity and modest bank facilities eliminates insolvency overhang, dramatically compressing credit default spreads and unlocking substantial equity multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry from distressed historical lows. |
| BetterHelp commercial insurance network pivot | Innovation And Product | +24% | +25% | Transitioning BetterHelp from direct-to-consumer cash subscriptions toward contracted commercial insurance unlocks access to over 150 million covered lives. While initial clinician credentialing creates temporary capacity bottlenecks, in-network reimbursement lowers member acquisition costs, lengthens retention curves, and replaces volatile consumer advertising auctions with durable, recurring payer-sponsored session volume across the five-year horizon. |
| Operational overhead and compensation discipline | Operational Efficiency | +18% | +22% | Executive leadership has aggressively curtailed corporate overhead and trimmed stock-based compensation by over thirty percent year-over-year. Concurrently, deploying automated intake routing and clinical documentation tools reduces clinician visit completion times. This administrative austerity closes the chasm between GAAP net loss and adjusted EBITDAadjusted ebitdaEBITDA modified to exclude selected items that management considers non-recurring or not representative of ongoing operations.View full glossary entry, systematically enhancing operational cash flow conversion over the forecast cycle. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Consumer therapy cash pay attrition | Competitive Positioning | -22% | -24% | BetterHelp faces relentless structural headwinds as inflationary pressures squeeze discretionary household mental health budgets. Paying users fell eleven percent year-over-year as cash-pay subscribers churned, while aggressive digital advertising competition inflated acquisition costs. This persistent consumer fatigue depresses segment revenue, exerting an enduring drag on consolidated earnings until commercial insurance reimbursement achieves critical scale. |
| Replacement debt coupon step up | Macroeconomic And Macrofinancial | -18% | -16% | The 2027 convertible notes carry an ultra-low 1.25% coupon. Refinancing any residual portion in a restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry with policy rates near 4% will require market rates between 7% and 9%. This coupon step-up will add tens of millions in annual cash interest expense, directly compressing net income and constraining discretionary capital reinvestment. |
| Virtual care pricing commoditizationcommoditizationThe process where services become indistinguishable, leading to price-based competition and severe margin erosion.View full glossary entry pressure | Sector And Industry | -15% | -14% | Basic telehealth consultations face aggressive commoditizationcommoditizationThe process where services become indistinguishable, leading to price-based competition and severe margin erosion.View full glossary entry from regional hospital health systems, retail pharmacy clinics, and captive payer virtual networks like Optum. Health plan sponsors demand price concessions and shift contracts from fixed per-member subscription fees to utilization-based visit models. This pricing compression limits organic revenue expansion and caps long-term gross margingross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry growth across commercial accounts. |
| Capitalized software free cash flattery | Management And Governance | -12% | -10% | Reported free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry is heavily flattered by accounting conventions, as capitalized software development represents over ninety percent of total capital spending. Deducting software additions reduces true trailing cash generation from $225 million toward $130 million. Investors normalizing for recurring development expenditures will adjust cash flow yields downward, dampening potential valuation multiple expansionvaluation multiple expansionAn increase in valuation ratios such as P/E or EV/EBITDA, often driven by stronger growth or lower perceived risk.View full glossary entry. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Credit freeze forced equity dilutionequity dilutionThe reduction in ownership percentage for existing shareholders caused by the issuance of new shares.View full glossary entry | 22% | -50% | Dislocations across corporate credit markets coincide with operational cash deterioration ahead of the June 2027 convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry maturity. Unable to issue replacement credit facilities on viable terms and lacking sufficient unrestricted liquidity, management is forced into a punitive rescue financing involving deeply discounted equity-linked instruments. This restructuring would heavily dilute existing common shares, permanently crushing per-share value despite existing cash reserves holding probability below half. |
| BetterHelp regulatory and privacy penalties | 20% | -45% | Federal regulators or state attorneys general initiate sweeping enforcement actions over consumer data privacy, tracking pixels, or therapist credentialing compliance across online therapy platforms. Imposed statutory fines, mandated operational curbs, and reputational fallout would collapse user onboarding funnels and prompt commercial insurers to freeze reimbursement partnerships. While comprehensive compliance remediation keeps probability below fifty percent, materialization would decimate behavioral health cash generation and trigger major impairments. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Strategic private equity buyout bid | 28% | +65% | A private equity consortium or commercial payer launches an unsolicited takeover bid, capitalizing on depressed valuations near 0.5 times sales and predictable B2B cash flows. A buyer could carve out BetterHelp and optimize Integrated Care away from public scrutiny. The event remains below fifty percent probability due to antitrust scrutinyantitrust scrutinyAntitrust scrutiny is regulatory examination of conduct, pricing, mergers, or market power that may reduce competition or harm consumers.View full glossary entry, but would command a substantial control premium. |
| Commercial GLP1 companion program breakthrough | 25% | +55% | Commercial payers mandate digital lifestyle and clinical companion programs for reimbursed anti-obesity and cardiometabolic medications starting in 2027. Leveraging its established chronic condition architecture, the enterprise captures preferred vendor status across national employer coalitions. This catalytic alignment injects hundreds of thousands of high-margin subscriptions into Integrated Care, accelerating organic revenue into double digits. Probability remains below fifty percent because payers frequently evaluate internal disease management alternatives. |
Company Financial Analysis
Teladoc Health Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Reported financial results present a striking contrast between headline accounting deficits and resilient operational cash production. For fiscal 2025, revenue contracted slightly to $2.53 billion, while reported net losses narrowed dramatically to $200 million as massive historical goodwill write-offs ended. Second-quarter 2026 revenue of $607 million reflected continued contraction in consumer therapy, but enterprise healthcare services held steady. Crucially, headline accounting losses are driven by non-cash amortization from past acquisitions rather than ongoing cash burn. The core business generated $225 million in trailing cash flow, though factoring in internal software spending lowers true underlying cash generation closer to $130 million. This cash cushion stabilizes the company while management reshapes operations.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 2.5B | USD -200.3M | USD 285.5M |
| 2024 | USD 2.6B | USD -1B | USD 282.9M |
| 2023 | USD 2.6B | USD -220.4M | USD 193.7M |
| 2022 | USD 2.4B | USD -13.7B | USD 172.8M |
| 2021 | USD 2B | USD -428.8M | USD 185.5M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | -- | TTM | Loss-making | USD / USD |
| 2024 | -- | TTM | Loss-making | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Profitability metrics reveal a dramatic split between operating units. Consolidated gross margins remain structurally high near 70%, proving that core virtual clinical consultations retain attractive underlying economics. However, operating margins diverged sharply in the second quarter of 2026: Integrated Care maintained a solid 16.5% adjusted EBITDA margin, while consumer-focused BetterHelp fell to breakeven at 0.2%. This divergence stems from inflated advertising costs in direct-to-consumer therapy, which management addressed by reducing marketing spend. Shifting therapy into in-network commercial insurance reduces member acquisition costs. As non-cash acquisition amortization rolls off and cost discipline takes hold, consolidated operating profitability is positioned to rebound gradually.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD -263M | -10.4% | -7.9% |
| 2024 | USD -1B | -39.7% | -39.0% |
| 2023 | USD -248.6M | -9.6% | -8.5% |
| 2022 | USD -13.2B | -548.4% | -567.5% |
| 2021 | USD -265.6M | -13.1% | -21.1% |
Balance sheet and leverage
AI Review
The balance sheet presents a sharp contrast between substantial liquid resources and an impending debt maturity. Teladoc held $774 million in cash equivalents at the end of June 2026 against $996.7 million in convertible senior notes maturing in June 2027. An undrawn $300 million credit facility provides total gross liquidity exceeding $1.07 billion. This ample liquidity disproves widespread market fears of imminent bankruptcy. Management has adequate capacity to retire the notes using accumulated cash and conservative bank loans without diluting shareholders. However, repaying the debt will reduce cash balances and raise interest expenses on replacement borrowing, making ongoing operational cash generation essential.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 1B | USD 781.1M | USD 259.1M net debt | 2.69x |
| 2024 | USD 1.6B | USD 1.3B | USD 286.3M net debt | 1.77x |
| 2023 | USD 1.6B | USD 1.1B | USD 468.6M net debt | 3.54x |
| 2022 | USD 1.6B | USD 918.2M | USD 668.7M net debt | 3.22x |
| 2021 | USD 1.3B | USD 896M | USD 386.7M net debt | 3.70x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Physical capital expenditure appears almost nonexistent, with traditional equipment purchases absorbing only 0.35% of revenue in 2025 and just $2.6 million during the first half of 2026. This reflects a virtual delivery model that requires minimal brick-and-mortar investment compared to physical hospital networks. However, real capital intensity is concentrated in software development, which consumed $62.2 million during the first half of 2026. Management has redirected investment away from aggressive consumer marketing toward platform automation and clinical intelligence tools. This software discipline protects near-term cash reserves ahead of upcoming bond maturities, though continuing technology spending remains essential to prevent platform obsolescence against rivals.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 8.9M | USD 277.9M |
| 2024 | USD 10.8M | USD 307.3M |
| 2023 | USD 156.3M | USD 348.5M |
| 2022 | USD 16.5M | USD 333.6M |
| 2021 | USD 8.5M | USD 311.9M |
Quarterly Forecast Scenarios
Teladoc Health Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $5.796 | $6.453 | $6.804 | $750.26 | |
| $5.4482 | $6.8742 | $8.0287 | $736.44 | |
| $5.6117 | $7.5395 | $9.233 | $743.40 | |
| $5.9484 | $7.9272 | $10.16 | $755.15 | |
| $6.1863 | $8.3436 | $10.97 | $776.22 | |
| $6.4956 | $8.7921 | $11.63 | $787.13 | |
| $6.6905 | $9.2634 | $12.44 | $802.83 | |
| $6.5744 | $9.5438 | $13.06 | $812.05 | |
| $6.9031 | $9.9822 | $13.85 | $839.18 | |
| $7.1792 | $10.41 | $14.40 | $850.50 | |
| $7.4564 | $10.82 | $15.12 | $872.39 | |
| $7.6801 | $11.11 | $15.57 | $885.51 | |
| $7.8337 | $11.52 | $16.20 | $909.56 | |
| $7.9904 | $11.94 | $16.85 | $916.13 | |
| $7.826 | $12.30 | $17.35 | $936.51 | |
| $8.1391 | $12.55 | $17.87 | $947.34 | |
| $8.4646 | $13.01 | $18.85 | $969.59 | |
| $8.5618 | $13.43 | $19.79 | $979.99 | |
| $8.3049 | $13.75 | $20.58 | $999.60 | |
| $8.471 | $14.05 | $21.20 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
Independent assessments converge on a critical operational dichotomy: durable enterprise Integrated Care subscription cash flows contrast with sharp consumer therapy revenue decay. Most perspectives acknowledge that existing balance-sheet liquidity and undrawn credit capacity provide sufficient runway to resolve the impending 2027 convertible debt maturity. However, relative weighting heavily rewards analyses that rigorously adjust free cash flow for aggressive software capitalization and executive stock compensation rather than uncritically accepting headline trailing cash metrics. The strongest contrarian case cautions that higher replacement borrowing coupons in a restrictive monetary regime will permanently compress equity earnings once low-coupon debt matures. Conversely, unverified assumptions regarding imminent bankruptcy or effortless multiple expansion to pre-pandemic peaks are systematically downweighted. Relative allocations prioritize forensic scrutiny of working capital and debt rollover mechanics over speculative takeover narratives.
Universal Investor AI
The Polymath
GPT-6 AstraWeighted highest alongside the primary polymath report for exceptional evidentiary rigor, reconstructing normalized free cash flow by expensing capitalized software, modeling equity dilution, and establishing a grounded, realistic valuation framework.
Universal Investor AI
The Polymath
Opus 5Receives superior weighting due to forensic examination of software capitalization flattery, realistic normalization of free cash flow, and detailed segmentation between high-margin Integrated Care and deteriorating direct-to-consumer therapy ahead of the critical 2027 debt maturity.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashMerits substantial weighting for rigorous segment EBITDA decomposition, realistic appraisal of commercial insurance transition timelines, and disciplined balance-sheet tracking that demonstrates non-dilutive debt retirement capability from internal liquidity.
Michael Burry AI
The Vulture
Gemini 3.8 FlashMerits significant allocation for disciplined balance-sheet forensics, accurate appraisal of convertible debt redemption capacity using existing cash, and clear identification of therapist recruitment bottlenecks in behavioral health.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashSupported by solid forensic tracking of commercial in-network coverage expansion, administrative overhead cuts, and executable debt retirement steps, providing strong evidence-based causal links between operational stabilization and multiple recovery.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashMerits high weighting for incisive appraisal of regulatory telehealth extension dynamics, payer insourcing frictions, and detailed mechanics of replacement financing costs in a restrictive central bank monetary regime.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashAssigned moderate weight for sound identification of core enterprise switching costs and balance-sheet liquidity, though limited by uncritical reliance on headline trailing cash flow without adjusting for heavy historical capitalized software development outlays.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashReceives balanced weighting for valuable analysis of executive payer restructuring and chronic care cross-selling dynamics, but downweighted for overly optimistic multiple expansion assumptions in an elevated interest rate environment.
Elon Musk AI
The Visionary
Gemini 3.8 FlashWeighted moderately for a pragmatic assessment of enterprise healthcare inertia and aggressive overhead pruning, though discounted for treating clinical software commoditization and competitive AI threats with insufficient balance-sheet depth.
Universal Investor AI
The Polymath
Gemini 3.8 FlashAssigned moderate weight for coherent analysis of multi-condition bundling and commercial payer expansion, though constrained by optimistic multiple normalization targets that overlook prospective replacement debt coupon step-ups.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashReceives balanced allocation for recognizing the enterprise cash-harvesting turnaround and downside book value protections, tempered by somewhat generic treatments of AI clinical disintermediation and stock-based compensation dilution.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashWeighted moderately for robust macroeconomic contextualization and enterprise chronic care stickiness analysis, but tempered by aggressive price-to-sales multiple targets that exceed historical post-bubble medtech reorganization standards.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashReceives balanced weighting for detailed examination of provider credentialing bottlenecks and visit-based contract transitions, balanced against an aggressive projection of terminal valuation multiple recovery that slightly understates long-term competitive payer insourcing.
Universal Investor AI
The Polymath
Gemini 3.8 FlashAssigned lower weight due to substantial reliance on unadjusted headline cash flow figures and repeated debt-buyback assumptions, though credited for recognizing enterprise contract switching costs and short-term liquidity cushions.
Research Provenance
References & Context
This Teladoc Health consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 52 deduplicated sources retained for this batch.
- 01Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 020001477449 false 0001477449 2020-05-18 2020-05-19 iso4217:USD xbrli:shares iso4217:USD xbrli:sharessec.gov
- 03Secsec.gov
- 04tdoc-20251231sec.gov
- 05tdoc-20260630sec.gov
- 06Teladoc Health, Inc. - Form 10-Q - FY2026sec.gov
- 07Teladoc Health, Inc. - Teladoc Health Reports Second Quarter 2026 Resultsir.teladochealth.com
- 08Dealroom.co | BetterHelp president sells entire $71K Teladoc stake, exits position completelyapp.dealroom.co
- 09Let's Buy BetterHelpbeyondbillions.substack.com
- 10TDOC Stock Quote Price and Forecast | CNNcnn.com
- 11Teladoc Health CEO lays out telehealth giant's M&A strategy following first year at the helmfiercehealthcare.com
- 12Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path? (TDOC)finance.yahoo.com
- 13Teladoc Health Q2 Earnings Call Highlightsfinance.yahoo.com
- 14Teladoc Health, Inc. Q2 2026 Earnings Call Summaryfinance.yahoo.com
- 15Teladoc Q2 2026 slides: revenue miss drives sharp stock decline By Investing.cominvesting.com
And 37 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.